Malassezia species and human epidermal cells

Malassezia species are lipophilic, commensal yeasts that constitute a significant portion of the human skin microbiome, particularly in sebum-rich regions (PMID: 28914266). The interaction between Malassezia and human epidermal cells, specifically keratinocytes, represents a complex host-pathogen interface where fungal metabolic activities influence host skin physiology. Malassezia secretes various enzymes, including lipases and proteases, which degrade skin lipids into free fatty acids that can disrupt the epidermal barrier and induce inflammation (PMID: 15692300). Keratinocytes respond to these stimuli by activating innate immune pathways, notably through Toll-like receptor 2 (TLR2) and Dectin-1, leading to the release of pro-inflammatory cytokines like IL-8 and TNF-alpha (PMID: 19172135). This biological interaction is central to the pathogenesis of several common dermatological conditions, such as seborrheic dermatitis, pityriasis versicolor, and atopic dermatitis (PMID: 32102215). In these states, the balance between commensalism and pathogenicity is disrupted, often due to fungal overgrowth or altered host sensitivity. Therapeutic management typically targets this interface by using antifungal agents, such as ketoconazole or zinc pyrithione, to reduce fungal burden, or topical corticosteroids to dampen the host's inflammatory response (PubChem CID 3823). Understanding the molecular cross-talk between Malassezia and epidermal cells is crucial for developing targeted therapies that restore skin homeostasis without broadly disrupting the microbiome.

Other names

Malassezia-keratinocyte interactionMalassezia-host interfaceMalassezia-skin interaction

Inhibition of fungal lanosterol 14-alpha-demethylase (ergosterol synthesis) and modulation of host epidermal cytokine production